Zimmer Biomet Holdings Valuation
Is ZBH * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ZBH * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ZBH * (MX$2080.72) is trading above our estimate of fair value (MX$1697.39)
Significantly Below Fair Value: ZBH * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ZBH *?
Other financial metrics that can be useful for relative valuation.
What is ZBH *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$24.71b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.1x |
Enterprise Value/EBITDA | 12.5x |
PEG Ratio | 2.8x |
Price to Earnings Ratio vs Peers
How does ZBH *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 44.4x | ||
4543 Terumo | 39.9x | 12.1% | JP¥4.0t |
STMN Straumann Holding | 79.7x | 23.8% | CHF19.6b |
GEHC GE HealthCare Technologies | 25x | 14.7% | US$34.8b |
RMD ResMed | 32.8x | 13.0% | US$31.9b |
ZBH * Zimmer Biomet Holdings | 24.1x | 8.5% | Mex$24.7b |
Price-To-Earnings vs Peers: ZBH * is good value based on its Price-To-Earnings Ratio (24.1x) compared to the peer average (44.5x).
Price to Earnings Ratio vs Industry
How does ZBH *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: ZBH * is good value based on its Price-To-Earnings Ratio (24.1x) compared to the Global Medical Equipment industry average (28.3x).
Price to Earnings Ratio vs Fair Ratio
What is ZBH *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 24.1x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ZBH *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.